High‑intent prospects are sitting in your pipeline, but the deals keep slipping into “no decision.” The product is strong, the business case is rational, and yet buying committees stall, re‑scope, or default to incumbents. For CEOs running B Corporations and venture‑backed startups with high‑value solutions, this is not a sales inconvenience, it is an existential constraint on growth.
Drawing on 27 years of front‑line enterprise Business Development experience, Rich Laster argues that what looks like price resistance is more often structured skepticism. The buying organization is not ‘confused.’ It is unconvinced that your upside is real, your downside is contained, and your team will still be there when something breaks. When you treat this as a messaging problem, you discount. When you treat it as a design problem, you architect sales plays that convert skeptics into sponsors.
The CEO’s Real Problem: Skepticism, Not Price
Across B2B technology, sales cycles have lengthened and buying groups have expanded. A 2026 SaaS pipeline study of 939 companies reports a median sales cycle of 84 days, with enterprise deals often extending beyond 180 days as security, legal, and finance add incremental scrutiny.¹ At the same time, research on B2B technology buyers shows that most do not believe vendors are fully honest, and that candid discussion of limitations is a stronger trust signal than polished claims.² In practice, your revenue engine is pushing against a market that assumes your pricing is unfair, your roadmap is optimistic, and your “ROI calculator” is biased.
Ivy League research has documented this trust gap for years. Wharton scholars have shown that buyers routinely suspect firms of price gouging, especially when they perceive that companies are exploiting information advantages.³ Harvard researchers, looking at price framing, have demonstrated that nominal “original” prices can anchor perceived value, even when those prices are artificial, which further complicates how buyers interpret high list prices.⁴ In an environment shaped by these biases, a premium offer is automatically placed in the “prove it” bucket.
For the CEO, the agitation is threefold. First, board expectations are usually tied to a model that assumes historic conversion rates, not today’s skeptical committees. Second, high‑intent prospects absorb disproportionate sales and founder time, so stalled deals bleed organizational focus. Third, as a B Corporation or mission‑driven venture, you are often pricing with a view to long‑term impact and talent sustainability, yet you are judged by buyers conditioned by years of opaque pricing and promotional theater.
Why High‑Cost Offers Trigger Structured Skepticism
Customer experience research from Wharton indicates that confidence follows a U‑shaped trajectory as buyers gain experience: they begin overconfident, then their confidence dips as they realize what they do not know, and only later rebounds with expertise.⁵ High‑cost, high‑impact purchases tend to occur precisely in this “confidence trough.” Buyers know enough to be wary, but not enough to evaluate competing claims quickly. The rational response is to default to caution.
Several dynamics follow from this.
- Buying committees expand, because organizations seek to pool partial expertise. Gartner has reported that the average B2B purchase involves more than six stakeholders, which directly extends cycle time and diffuses accountability.¹
- Risk weighting flips. The perceived downside of a failed implementation, reputationally and operationally, looms larger than the modeled upside in a spreadsheet. Behavioral research on fairness and trust suggests that people penalize perceived opportunism more harshly than they reward perceived generosity.³
- Vendor narratives are discounted. Studies of B2B buyers find that fewer than half consider vendor claims fully credible, creating what some analysts call a persistent “evidence gap” in enterprise selling.²
The practical implication is that your revenue problem is not “our price is too high.” It is “our sales motion does not give skeptical, risk‑sensitive buyers enough structured evidence, control, and off‑ramps to say yes.”
The Skeptic Conversion Model: A Framework For High‑Value Selling
Over nearly three decades of selling and advising on complex deals, Rich Laster has refined a simple but rigorous model for converting skeptical buying groups. It has four stages: Decode, De‑Risk, Demonstrate, and Decide. Each stage aligns the sales play with how skeptical buyers actually process risk.
Decode: Map Skepticism, Not Just Pain
Most discovery processes begin by mapping the customer’s explicit pains and desired outcomes. That is necessary, and insufficient. In high‑value contexts, you must also map the buyer’s skepticism. This is rarely a known practice to Founders but, has a great impact on the quality of relationship B2B companies have with their clients.
In practice, this means probing explicitly for:
- Failure narratives. “Where has a similar initiative gone wrong here or elsewhere?”
- Political constraints. “Who pays the reputational cost if this does not work?”
- Trust triggers. “Which evidence sources carry weight for you: internal pilots, peer references, external benchmarks, or something else?”
Wharton and Columbia research on choice overload and decision confidence shows that when stakes are high and options are complex, buyers seek mechanisms that narrow the field and legitimize a decision to cautious peers.⁶ The decoding stage is where you uncover which mechanisms will actually move this specific committee.
A practical tool at this stage is a Skeptic Map: a one‑page document that lists stakeholders, their explicit goals, their implicit fears, and the evidence they would need to move from “skeptical” to “open‑minded.” Sales leadership can require that no proposal is issued until a Skeptic Map is completed and reviewed.
De‑Risk: Engineer Safety Before You Argue Value
Research from Harvard’s Program on Negotiation warns that an excessive focus on price in sales negotiations crowds out opportunities to create value on non‑price dimensions like risk allocation, timing, and support.⁷ For skeptical buyers, the fastest path to progress is often not a lower price but, a lower perceived downside.
Effective de‑risking strategies include:
- Phased commitments, such as a defined 90‑day outcome pilot with pre‑agreed exit criteria.
- Asymmetric guarantees, where you absorb more downside early, then rebalance economics as value is proven.
- Explicit failure protocols, outlining what happens if key assumptions do not hold, including reconfiguration or rollback paths.
These mechanisms are not promotional gestures. They are governance structures that give CFOs and risk officers a defensible rationale for proceeding, consistent with findings that transparency and fairness in pricing and terms significantly increase customer satisfaction and loyalty.⁸ When you design the deal so that “worst case” is survivable and reversible, you neutralize the fear that has been quietly vetoing your opportunity.
Demonstrate: Replace Claims With Decision‑Grade Evidence
Surveys of B2B buyers consistently show that peers, independent analysts, and transparent case data rank above vendor messaging in influence.²⁹ In an era where roughly 60 percent of buyers report distrust in vendor claims,⁹ the quality of your evidence often matters more than the eloquence of your pitch.
A disciplined demonstration strategy hinges on three elements.
- Evidence architecture. For each major buyer objection, specify the evidence type that best addresses it: quantified case study, customer reference call, third‑party benchmark, or sandbox access.
- Operational specificity. Generic ROI ranges rarely move serious committees. What does move them are line‑item impacts tied to their model, for example, “reduction in manual QA hours in this plant” rather than “productivity uplift.”
- Negative capability. Willingness to acknowledge what your product does not do, or where results have been mixed, is a counterintuitive trust accelerator, consistent with research that candor around limitations is one of the most trusted information sources.²
At this stage, many teams benefit from structured tools. An example is a “Decision Evidence Dossier,” a curated bundle of 6 to 10 assets mapped to the customer’s top risks and KPIs, ordered to match their internal review sequence. Well‑run teams treat this as a living asset, refined after every major deal review.
Decide: Orchestrate Internal Consensus, Do Not Assume It
Even when buyers are convinced on the merits, complex deals fail because internal consensus is not orchestrated. Studies of buying committees show that more than half of opportunities that stall do so in internal deliberations, not in vendor meetings.¹
The Decide stage shifts your sales play from persuasion to coalition building. Effective methods include:
- Pre‑work templates that economic buyers can circulate ahead of a final meeting, capturing each stakeholder’s support level, primary concern, and required condition to approve.
- “Red‑team” sessions where you explicitly invite a skeptical stakeholder to stress‑test the proposal, then co‑author mitigation steps.
- Implementation previews that bring delivery leaders into the conversation early, which reduces fear that the “A‑team” disappears at signature.
From a governance lens, this is where you help the customer construct a decision that looks defendable to their own leadership. When your sales process consistently equips buyers to tell a coherent internal story about upside, downside, and execution, your close rates change fundamentally, without relying on broad discounting.
The Skeptic Conversion Scorecard: A Practical Diagnostic Tool
To operationalize this model, CEOs can deploy a simple scoring system across late‑stage opportunities. For each in‑flight deal, rate the following dimensions from 1 (weak) to 5 (strong).
- Skeptic Insight: Depth of understanding of each key stakeholder’s fears, past scars, and decision style.
- Risk Architecture: Strength of the contractual and structural mechanisms that limit downside in early phases.
- Evidence Quality: Relevance and credibility of the evidence provided relative to the committee’s preferences.
- Consensus Design: Clarity of the internal decision path, including explicit buy‑in from finance, security, and operations.
- Implementation Confidence: Demonstrated confidence that your team can execute, as perceived by the buyer, not by you.
Aggregate scores below 15 suggest that the deal is still in a persuasion phase, no matter what your CRM stage label says. Scores above 20 are characteristic of opportunities where decisions, yes or no, occur in defined timeframes and with fewer surprises. Over a quarter or two, this scorecard becomes a leading indicator of revenue reliability, informing both pipeline quality and enablement investments.
Addressing Common Objections To This Approach
Some CEOs worry that too much transparency about limitations or downside risk will weaken their negotiating position. The research record suggests the opposite. Wharton and Harvard studies on fairness and trust repeatedly find that perceived opportunism erodes loyalty and lifetime value more than any single concession ever recovers.³⁴ In high‑stakes B2B contexts, buyers are more likely to reward vendors who make constraints explicit, then co‑design realistic paths to value.
Another objection is that engineering pilots, phased commitments, and evidence dossiers is operationally expensive for lean early‑stage teams. This is valid, which is why these plays should be reserved for well‑qualified, high‑value opportunities. The trade‑off, however, is favorable. The incremental cost of structured skeptic conversion is usually far smaller than the cumulative cost of months of founder time spent on deals that die quietly in committee.
Finally, some fear that adopting such a rigorous model will slow down “easy wins.” In practice, the opposite tends to occur. By clarifying which signals indicate a truly high‑skeptic, high‑value deal, teams can also identify low‑skeptic environments where a streamlined version of the model is sufficient. The discipline of mapping skepticism and risk often reveals segments or use cases where your proposition is inherently less controversial and therefore more scalable.
What This Means For CEOs And Investors
For B Corporation and venture‑backed CEOs, the real frontier in revenue scalability is not more outreach, more demos, or more aggressive discounting. It is an institutional capability to decode, de‑risk, demonstrate, and orchestrate decisions for inherently skeptical, multi‑stakeholder buyers.
Investors increasingly assess not just the top‑of‑funnel engine, but the company’s ability to navigate high‑stakes consensus selling. Teams that adopt a Skeptic Conversion Model, supported by a practical scorecard and clear operating norms, convert the same pipeline into more predictable revenue with less volatility. They also build reputational capital as transparent, trustworthy partners, which Ivy League research links directly to long‑term loyalty and pricing power.³⁸
The next phase of growth will not reward the loudest story. It will reward the teams that respect buyer skepticism as a rational response to risk, then design sales plays that transform that skepticism into informed, confident commitment. CEOs who take this work seriously will find that their “high‑cost” offers begin to look, in the eyes of their best customers, like the safest option on the table.
Footnotes
- Optifai, “B2B Sales Cycle Length: 14‑180 Days by Deal Size,” Optifai Pipeline Study, 2026, N = 939 B2B SaaS companies.
- Lisa Bolton et al., “A Great Bargain or a Big Rip‑off? Consumers’ Perceptions of Price Fairness,” discussed in Knowledge at Wharton.
- Donald Ngwe, “Bargain Hunters Beware: A Store’s ‘Original Price’ Might Not Be After All,” Harvard Business School Working Knowledge, 2018.
- Jonah Berger, “The Trajectory of Confidence: Experience, Certainty, and Consumer Choice,” Journal of Marketing Research, summarized in Knowledge at Wharton, 2026.
- Sheena Iyengar, “A Better Choosing Experience,” Columbia Business School research on choice and participation.
- “4 Sales Negotiation Traps, and How to Overcome Them,” Program on Negotiation at Harvard Law School, 2025.
- “A Survey of 1,700 Companies Reveals Common B2B Pricing Mistakes,” Harvard Business Review, 2018.
- TrustRadius, “Almost 60% of B2B Buyers Do Not Trust Vendors,” 2017.
Discover more from GrowExpand.com
Subscribe to get the latest posts sent to your email.